Rayleen M Lewis1,2, Lauri E Markowitz1, Julia W Gargano1, Martin Steinau3, Elizabeth R Unger3. 1. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta. 2. Synergy America, Inc, Duluth. 3. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
Background: Differences in human papillomavirus (HPV) prevalence among males and females have been reported. Using the 2013-2014 National Health and Nutrition Examination Survey, we evaluated sex differences in prevalence overall and by demographic and sexual behavior characteristics. Methods: Self-collected penile and cervicovaginal swabs from participants aged 14-59 were tested for HPV DNA. Prevalences of any HPV and high-risk HPV (HR-HPV) were estimated for sexually experienced males and females. Overall and in models stratified by demographic characteristics and behaviors, prevalence was compared in males and females using prevalence ratios (PR). Results: Overall, males had higher prevalence than females of any HPV (PR, 1.14; 95% confidence interval [CI], 1.03-1.27) and HR-HPV (PR, 1.24; 95% CI, 1.07-1.43). Prevalences were lower among males than females at ages 14-19 and higher at ages 40-49 and 50-59. Sex differences in models stratified by race/ethnicity, poverty, sexual behaviors, and smoking were observed. After adjusting for lifetime sex partners, most sex differences were attenuated, but males had lower prevalences at ages 14-19 and 20-24 and higher HR-HPV prevalence among non-Hispanic blacks. Conclusions: Any HPV and HR-HPV prevalences were significantly higher in males; sex differences varied by age group and race/ethnicity. Lifetime partners explained many of the differences by sex. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Background: Differences in human papillomavirus (HPV) prevalence among males and females have been reported. Using the 2013-2014 National Health and Nutrition Examination Survey, we evaluated sex differences in prevalence overall and by demographic and sexual behavior characteristics. Methods: Self-collected penile and cervicovaginal swabs from participants aged 14-59 were tested for HPV DNA. Prevalences of any HPV and high-risk HPV (HR-HPV) were estimated for sexually experienced males and females. Overall and in models stratified by demographic characteristics and behaviors, prevalence was compared in males and females using prevalence ratios (PR). Results: Overall, males had higher prevalence than females of any HPV (PR, 1.14; 95% confidence interval [CI], 1.03-1.27) and HR-HPV (PR, 1.24; 95% CI, 1.07-1.43). Prevalences were lower among males than females at ages 14-19 and higher at ages 40-49 and 50-59. Sex differences in models stratified by race/ethnicity, poverty, sexual behaviors, and smoking were observed. After adjusting for lifetime sex partners, most sex differences were attenuated, but males had lower prevalences at ages 14-19 and 20-24 and higher HR-HPV prevalence among non-Hispanic blacks. Conclusions: Any HPV and HR-HPV prevalences were significantly higher in males; sex differences varied by age group and race/ethnicity. Lifetime partners explained many of the differences by sex. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Lauri E Markowitz; Gui Liu; Susan Hariri; Martin Steinau; Eileen F Dunne; Elizabeth R Unger Journal: Pediatrics Date: 2016-02-22 Impact factor: 7.124
Authors: Anna R Giuliano; Alan G Nyitray; Aimée R Kreimer; Christine M Pierce Campbell; Marc T Goodman; Staci L Sudenga; Joseph Monsonego; Silvia Franceschi Journal: Int J Cancer Date: 2014-07-26 Impact factor: 7.396
Authors: Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: Anil K Chaturvedi; Hormuzd A Katki; Allan Hildesheim; Ana Cecilia Rodríguez; Wim Quint; Mark Schiffman; Leen-Jan Van Doorn; Carolina Porras; Sholom Wacholder; Paula Gonzalez; Mark E Sherman; Rolando Herrero Journal: J Infect Dis Date: 2011-04-01 Impact factor: 5.226
Authors: Gui Liu; Susan Hariri; Heather Bradley; Sami L Gottlieb; Jami S Leichliter; Lauri E Markowitz Journal: Sex Transm Dis Date: 2015-01 Impact factor: 2.830
Authors: John Doorbar; Wim Quint; Lawrence Banks; Ignacio G Bravo; Mark Stoler; Tom R Broker; Margaret A Stanley Journal: Vaccine Date: 2012-11-20 Impact factor: 3.641
Authors: Vidisha Singh; Beau Gratzer; Pamina M Gorbach; Richard A Crosby; Gitika Panicker; Martin Steinau; Raiza Amiling; Elizabeth R Unger; Lauri E Markowitz; Elissa Meites Journal: Sex Transm Dis Date: 2019-10 Impact factor: 2.830
Authors: Monica L Kasting; Shannon M Christy; Madison E Stout; Gregory D Zimet; Catherine E Mosher Journal: Clin Nurs Res Date: 2021-09-18 Impact factor: 1.724
Authors: Laura Fejerman; Amelie G Ramirez; Anna María Nápoles; Scarlett Lin Gomez; Mariana C Stern Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-05-04 Impact factor: 4.090
Authors: Humberto Parada; Andrew H Vu; Paulo S Pinheiro; Caroline A Thompson Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-28 Impact factor: 4.254
Authors: Navkiran K Shokar; Amy Doan; Jessica Calderon-Mora; Rajkumar Lakshmanaswamy; Subramani Ramadevi; Gurjeet S Shokar; Jennifer Molokwu; Adam Alomari; Alok Dwivedi Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302